Synlogic (NASDAQ:SYBX) Price Target Raised to $20.00

Synlogic (NASDAQ:SYBX) had its price target hoisted by Piper Jaffray Companies from $16.00 to $20.00 in a research report report published on Monday morning, The Fly reports. Piper Jaffray Companies currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on the company. Chardan Capital set a $10.00 price target on Arcimoto and gave the company a buy rating in a research report on Friday, April 12th. Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. Jefferies Financial Group lowered their price target on CommVault Systems to $65.00 and set a buy rating on the stock in a research report on Tuesday, April 30th. They noted that the move was a valuation call. HC Wainwright set a $126.00 price target on AnaptysBio and gave the company a buy rating in a research report on Monday, June 24th. Finally, Wedbush reaffirmed an outperform rating and issued a $21.00 price target on shares of Epizyme in a research report on Wednesday, June 12th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $20.00.

NASDAQ SYBX opened at $7.19 on Monday. Synlogic has a fifty-two week low of $5.75 and a fifty-two week high of $14.59. The company’s 50-day moving average is $8.23. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $195.49 million, a price-to-earnings ratio of -3.54 and a beta of 2.42.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.42 million. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. On average, analysts forecast that Synlogic will post -2.09 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in shares of Synlogic by 45.7% in the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 6,820 shares during the period. BlackRock Inc. boosted its holdings in shares of Synlogic by 33.4% in the fourth quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock valued at $8,750,000 after acquiring an additional 312,398 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Synlogic by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 6,129 shares during the period. Northern Trust Corp boosted its holdings in shares of Synlogic by 1.2% in the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after acquiring an additional 2,005 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Synlogic by 50.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock valued at $2,220,000 after acquiring an additional 105,628 shares during the period. 81.89% of the stock is currently owned by institutional investors.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Story: Why do commodities matter?

The Fly

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.